POSSIBILITY OF DRUG PREVENTION ANTHRACYCLINE-INDUCED CARDIOTOXICITY

Purpose. To estimate the possibility of trimethylhydrasine propionate using for prevention of acute doxorubicin-induced cariotoxicity in breast cancer patients. Material and methods. The study included 72 women (mean age – 51 ± 2.1 years) with breast cancer without significant pathology of the cardiovascular system. Main group consisted of 32 patients (mean age – 52 ± 2.2 years), which were injected intravenously trimethylhydrasine propionate 1000 mg 1 times/day for three days prior to chemotherapy. 40 patients of the control group (mean age – 50 ± 2.5 years) did not receive of cardioprotective therapy before chemotherapy. For the cancer treatment of these patients used doxorubicin in dose of 50 mg/m2  per course in combination with various drugs. All patients were studied by GATE SPECT before starting chemotherapy and at 1 hour after the first administration of doxorubicin. Results. Before the start of chemotherapy, none of the patients showed perfusion defects and contractility disorders. Baselines left ventricular contractility in control group and in main group was not different. After doxorubicin administration in the control group there was a decrease in left ventricular ejection fraction (LVEF) – from 65.5 ± 9.8 % to 61.8 ± 7.2 % (p<0.05), increase in left ventricular end-systolic volume – from 30.8 ± 16.7 ml to 34.2 ± 17.0 ml (p<0.05), reduction in the peak ejection rate – from 3.2 ± 0.8 EDV/s to 2.4 ± 0.5 EDV/s (p<0.05). In the main group after first course of chemotherapy statistically significant changes of left ventricular contractile function were not found. After administration of doxorubicin was found that 31 % patients of main group and 40 % patients of control group had a considerable (10% or more) reduction in LVEF.

GATE single photon emission tomography, anthracycline-induced cardiotoxicity, trimethylhydrasine propionate, prevention of cardiotoxicity, breast cancer

1. Kalvin’sh I.Ja. Mildronat is a mechanism of action and the prospects of its application. Riga: Grindeks, 2002. 112 p. [in Russian]

2. Lishmanov Yu.B., Chernov V.I., Krivonogov N.G., Efimova I.Yu., Vesnina J.V., Zavadovsky K.V., Minin S.M., Sazonova S.I., Skuridin V.S., Pankova A.N., Saushkin V.V., Ilyushenkova Yu.N., Efimova N.Yu.Radionuclide research methods in diagnostics of cardio-vascular diseases // Sibirskij medicinskij zhurnal (Tomsk). 2010. Vol. 25. (4). P. 8–13. [in Russian]

3. Matyash M.G., Kravchuk T.L., Vysotskaya V.V., Chernov V.I., Goldberg V.E. Antracycline-induced cardiotoxicity: Mechanisms of development and clinical manifestations // Sibirskij onkologicheskij zhurnal. 2008. № 6. P. 66–75. [in Russian]

4. National guideline in nuclear medicine / Eds. Yu.B. Lishmanov, V.I. Chernov, Tomsk: STT, 2010. Vol. 1. 290 p. [in Russian]

5. Chernov V.I., Kravchuk T.L., Zelchan R.V., Goldberg V.E. 99mTcMIBI myocardial Gate SPECT in the Detection of Acute and Chronic Cancer Treatment-Induced Cardiotoxicity // Medicinskaja radiologija i radiacionnaja bezopasnost’. 2012. № 4. P. 32–38. [in Russian]

6. Chernov V.I., Garganeeva A.A.,Vesnina J.V. Lishmanov Yu.B. Perfusion scintigraphy in assessment of results of course treatment with trimetazidine of patients with ischemic heart disease // Kardiologija. 2001. № 8. P. 14–16. [in Russian]

7. Adams M.J., Lipshultz S.E. Pathophysiology of anthracycline and radiation-associated cardiomyopathies: implications for screening and prevention // Pediatr. Blood Cancer. 2005. Vol. 44 (7). P. 600–606.

8. Berthiaume J.M., Wallace K.B. Adriamycin-induced oxidative mitochondrial cardiotoxicity // Cell Biol Toxicol. 2007. Vol. 23 (1). P. 15–25.

9. Bruynzeel A.M., Mul P.P., Berkhof J., Bast A., Niessen H.W., van der Vijgh W.J. The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice // Cancer Chemother. Pharmacol. 2006. Vol. 58 (5). P. 699–702.

10. Chaiswing L., Cole M.P., St Clair D.K., Ittarat W., Szweda L.I., Oberley T.D. Oxidative damage precedes nitrative damage in adriamycininduced cardiac mitochondrial injury // Toxicol. Pathol. 2004. Vol. 32 (5). P. 536–547.

11. Corna G., Santambrogio P., Minotti G., Cairo G. Doxorubicin paradoxally protects cardiomyocytes against iron-mediated toxicity: role of reactive oxygen species and ferritin // J. Biol. Chem. 2004. Vol. 279 (14). P. 13738–13745.

12. Drimal J., Zurova-Nedelcevova J., Knezl V., Sotníková R., Navarová J. Cardiovascular toxicity of the first line cancer chemotherapeutic agents: doxorubicin, cyclophosphamide, streptozotocin and bevacizumab // Neuro Endocrinol. Lett. 2006. Vol. 27 (suppl. 2). P. 176–179.

13. Hardenbergh P.H., Munley M.T., Bentel G.C., Kedem R., BorgesNeto S., Hollis D., Prosnitz L.R., Marks L.B. Cardiac perfusion changes in patients treated for breast cancer with radiation therapy and doxorubicin: preliminary results // Int. J. Radiat. Oncol. Biol. Phys. 2001. Vol. 49 (4). P. 1023–1028.

14. Hu K.Y., Yang Y., He L.H., Wang D.W., Jia Z.R., Li S.R., Tian W., Mao J., Li X.J., Zhang W. Prevention against and treatment of doxorubicininduced acute cardiotoxicity by dexrazoxane and schisandrin B // Yao Xue Xue Bao. 2014. Vol. 49 (7). P. 1007–1012.

15. Kwok J.C., Richardson D.R. Unexpected anthracycline-mediated alterations in iron-regulatory protein-RNA-binding activity: the iron and copper complexes of anthracyclines decrease RNA-binding activity // Mol. Pharmacol. 2002. Vol. 62 (4). P. 888–900.

16. Licata S., Saponiero A., Mordente A., Minotti G. Doxorubicin metabolism and toxicity in human myocardium: role of cytoplasmic deglycosidation and carbonyl reduction // Chem. Res. Toxicol. 2000. Vol. 13 (5). P. 414–420.

17. Mordente A., Minotti G., Martorana G.E., Silvestrini A., Giardina B., Meucci E. Anthracycline secondary alcohol metabolite formation in human or rabbit heart: biochemical aspects and pharmacologic implications // Biochem. Pharmacol. 2003. Vol. 66 (6). P. 898–98.

18. Sacco G., Giampietro R., Salvatorelli E., Menna P., Bertani N., Graiani G., Animati F., Goso C., Maggi C.A., Manzini S., Minotti G. Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity // Br. J. Pharmacol. 2003. Vol. 139 (3). P. 641–651.

19. Salvatorelli E., Menna P., Cascegna S., Liberi G., Calafiore A.M., Gianni L., Minotti G. Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies // J. Pharmacol. Exp. Ther. 2006. Vol. 318 (1). P. 424–433.

20. Schimmel KJ., Richel DJ., van den Brink RB., Guchealaar HJ. Cardiotoxicity of cytotoxic drugs // Cancer Treat. Rev. 2004. Vol. 30 (2). P. 181–191.

21. Sesti C., Simkhovich B.Z., Kalvinsh I., Kloner R.A. Mildronate, a novel fatty acid oxidation inhibitor and antianginal agent, reduces myocardial infarct size without affecting hemodynamics // J. Cardiovasc. Pharmacol. 2006. Vol. 47 (3). P. 493–499.

22. Simbre V.C., Duffy S.A., Dadlani G.H., Miller T.L., Lipshultz S.E. Cardiotoxicity of cancer chemotherapy: implications for children // Paediatr. Drugs. 2005. Vol. 7 (3). P. 187–202.

23. Sjakste N., Kleschyov A.L., Boucher J.L., Baumane L., Dzintare M., Meirena D., Sjakste J., Sydow K., Münzel T., Kalvinsh I. Endothelium and nitric oxide-dependent vasorelaxing activities of gamma-butyrobetaine esters: possible link to the antiischemic activities of mildronate // Eur. J. Pharmacol. 2004. Vol. 495 (1). P. 67–73.

24. Suzuki Y., Tokuda Y. Cardiovascular complications in oncology patients // Nippon Rinsho. 2003. Vol. 61 (6). P. 984–989.

25. Swain S.M., Whaley F.S., Gerber M.C., Weisberg S., York M., Spicer D., Jones S.E., Wadler S., Desai A., Vogel C., Speyer J., Mittelman A., Reddy S., Pendergrass K., Velez-Garcia E., Ewer M.S., Bianchine J.R., Gams R.A. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer // J. Clin. Oncol. 1997. Vol. 15. P. 1318–1322.